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Increasing evidence supports the concept that IL-1 playsa role in the atherosclerotic process. The development
of atherosclerotic lesions in the arterial walls of apolipo-
protein E (ApoE) or low-density lipoprotein (LDL) recep-
tor-deficient mice is markedly reduced in mice deficient in
the IL-1 receptor or in the IL-1 or IL-1 themselves. The
lesions are increased, however, in mice deficient in the
naturally occurring IL-1 receptor antagonist (1). More-
over, treatment of ApoE-deficient mice eating a high-fat
diet with anti-IL-1 antibodies prevents the arterial wall
lesions (2). In ApoE knockout mice, a bacterial challenge
worsens the disease but this is prevented in mice also de-
ficient in the IL-1 receptor (3). Similarly, in mice deficient
in the LDL receptor, the production of IL-1 and IL-1 by
macrophages is enhanced (4). The culprit in the formation
of atherosclerotic lesions is IL-1 produced by the myeloid
cells rather than the endotheliumormesenchymal cells (5).
Recent insights have suggested an important role of
IL-1 in atherosclerosis by inducing formation of the foam
cell, which enters the arterial wall and orchestrates the
inflammatory plaque. Indeed, foam cells are full of IL-1
as well as IL-1. In fact, within a few hours after eating a
fatty meal, there is increased IL-1 in the circulating
monocytes (6), independent of the high or low glycemic
composition of the meal (7). These in vivo clinical studies
are consistent with in vitro data of several reports dem-
onstrating an increase in gene expression and secretion of
IL-1 from fresh blood monocytes exposed to oxidized
LDL in vitro. Other lipids also induce IL-1, such as cho-
lesterol (CHOL) (8), chylomicrons (9), or triglycerides
(TG) (10). One can conclude that postprandial hyperlip-
idemia can be a signal for the circulating monocyte to
increase IL-1 production, and that IL-1-laden mono-
cytes entering a plaque as foam cells contribute to the
atherosclerotic process. It is also not unexpected that
caspase-1 contributes to the atherosclerotic process via
NLRP3 (NLR family, pyridine containing domain 3) (8).
In the paper by Delgado-Lista et al. (11), individuals
bearing the -1473 CC IL-1B polymorphism likely have a
pronouncedatherosclerotic processbecause this singlenu-
cleotide polymorphism is associated with increased fast-
ing lipids in the elderly population. In younger persons
with this polymorphism, when using a meal challenge,
higher circulating postprandial CHOL and TG concen-
trations were observed. Because of the well-known rela-
tionship between IL-1 activity and the circulating IL-6
concentrations, correlations were made with IL-6. How-
ever, readers of the paper by Delgado-Lista et al. (11)
should be aware that the elevated levels of IL-6 are more
than just a marker of IL-1 activity. Individuals treated
with monoclonal antibodies that block the IL-6 receptor
(tocilizumab) have increased LDL levels (12). Thus, the
study by Delgado-Lista contributes to the concept that
IL-1-driven IL-6modulate the regulation of serum lipids
by the liver.
Nevertheless, the authors concluded that elderly ho-
mozygotes for the rare allele have increased levels of fast-
ing TG. Due to the combination of increased TG and IL-6
levels,we also hypothesize that these patients overrespond
to the proinflammatory stimulus that occurs after a fatty
meal. These data have considerable implications for the
risk of cardiovascular events.
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These authors are rather familiar with effects of this
IL-1B polymorphism. They reported previously that in-
dividuals homozygous for the minor allele had a higher
risk for elevated blood pressure (P  0.05), as well as a
nonstatistically significant trend for a greater degree of
abdominal obesity and metabolic syndrome (P  0.07)
(13). There are several important clinical consequences of
the findings presented by Delgado-Lista et al. (11). The
increased release of proinflammatory cytokines after a
fatty meal in individuals bearing the -1473 CC variant in
IL-1B gene results in a chronic state of heightened inflam-
mation, which has been directly related to chronic pathol-
ogies such as atherosclerosis, coronary artery disease, or
metabolic syndrome (14). More specifically, the increase
in postprandial IL-6 concentration in individuals bearing
genetic variants of the IL-1B gene promoter bears witness
to an increased IL-1 bioactivity in these persons, because
IL-1 is known as the main driver of IL-6 synthesis (15).
IL-1 is one of the major proinflammatory cytokines in-
volved in atherosclerosis, metabolic syndrome, and insu-
lin resistance (16, 17).
The studybyDelgado-Lisa et al. (11) takesus, however,
one step further. In addition to identifying the postpran-
dial increase in proinflammatory cytokines in individuals
bearing the -1473 CC variant, the authors also investigate
the consequences of this process on TG and CHOL. Pro-
inflammatory cytokines such as TNF and IL-1 have been
known from the mid-1980s to have major effects on lipid
metabolism.TNF, initially also knownas cachectin, sup-
presses the level of adipocyte lipoprotein lipase (LPL) (18).
In addition, IL-1 was reported by the Cerami laboratory
(18) to reduce LPL. LPL suppression by proinflammatory
cytokines has been one of the most consistent findings in
patients with systemic inflammation, particularly in pa-
tients with sepsis (19). Due to the inhibition of LPL activ-
ity, the breakdown of lipids results in higher levels of TG
and very low-density lipoprotein in the circulation. Del-
gado-Lisa et al. (11) should be congratulated because they
link the earlier in vitro and animal studies to the human in
vivophysiologyby showing that a genetic variant of IL-1B
that is associatedwith an increased bioactivity also results
in higher TG and CHOL after a physiological meal.
What are the implications of these findings for human
physiology? On the one hand, the most obvious conse-
quence, as suggested by the authors themselves, is that the
resulting persistent heightened state of inflammation in
the individuals bearing the -1473 CC IL-1B variant may
contributebothdirectly (inflammation in the arterialwall)
and indirectly (high CHOL) to the atherogenic process. In
addition, the repeated postprandial increase in IL-1 bio-
activity in these individuals can have important effects on
glucose metabolism, with toxic effects on the pancreatic
-cells (20, 21) aswell as increased insulin resistance at the
level of the adipose tissue (16). Beyondmetabolic diseases,
the increased proinflammatory profile in individuals bear-
ing the -1473C allele can also have consequences on au-
toinflammatory diseases such as gout, a condition in
which IL-1 is known to play a crucial role in the patho-
genesis (22) and in which the synergism between uric acid
crystals and free fatty acids hasbeen shown tobenecessary
to induce IL-1 production and inflammation (23).
On the other hand, one should not forget that the cy-
tokine-induced cholesterol release has been most likely
evolved as a protective mechanism during infections. Pro-
inflammatory cytokines both activate host defense mech-
anisms and induce the release of lipoproteins that bindand
neutralize lipopolysaccharide and other toxic bacterial
products (24). High levels of CHOL and lipoproteins pro-
tect against infections both in experimental studies (25)
and in epidemiological studies in humans, especially those
ofoldage (19).Anunexplored consequenceof the findings
of Delgado-Lista et al. (11) is therefore the potential pos-
itive link between the -1473CC IL-1B polymorphism and
protection from complications of infectious diseases.
In conclusion, the study ofDelgado-Lisa et al. (11) pro-
vides an important piece of evidence, accumulated in a
clinical setting in humans to support the important role of
IL-1 for the lipid metabolism. The consequences of these
findings are broad. First, theyhelp to improveunderstand-
ingof thepathophysiologyofmetabolic and inflammatory
disorders inwhich IL-1 plays a role. Second, these findings
provide strong evidence for the rationale of using anti-IL-1
biological therapy in metabolic disorders and open the
door for adjustment of this therapy according to the ge-
netic status of an individual.
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